Explore evidence

64 %The study included 36 HIV-infected patients, including 23 women (64%), with a sex-ratio M/F of 0.57.

Côte d'IvoireVIH/sidaobserved January 2005-July 2015published 2018The Pan African medical journaleurope_pmcdocument of 9 observations

65.8 %Among 550 participants, 362 (65.8%) achieved virologic success at week 48.

Côte d'Ivoiretuberculose · VIH/sidapublished 2023AIDS (London, England)europe_pmcdocument of 6 observations

8 %Neuromeningeal cryptococcosis accounted for 8% of AIDS-defining reasons for hospitalization.

Côte d'Ivoireneuromeningeal cryptococcosis · VIH/sidapublished 2013Bulletin de la Societe de pathologie exotique (1990)europe_pmcdocument of 16 observations

85.4 %Among adolescent girls living with HIV in Côte d'Ivoire, 85.4% reported lack of information about the HPV vaccine as a barrier to vaccination.

Côte d'Ivoireinfection à HPV · VIH/sidaobserved 2024–2025HAL · Unilimdocument of 69 observations

84 %After 6 months of antiretroviral therapy, 84% of patients in Abidjan, Côte d'Ivoire reached viral-load undetectability.

Côte d'IvoireVIH/sidapublished 2008Bulletin of the World Health Organizationeurope_pmcdocument of 3 observations

2.9 %Of the 312 patients initially classified as HIV-2, 9 (2.9%) were reclassified as HIV-1&2.

Côte d'IvoireVIH/sidaobserved 2012published 2014Journal of the International AIDS Societyeurope_pmcdocument of 8 observations

10 %Among hospitalized HIV-positive adults in West Africa, cerebral toxoplasmosis was diagnosed in 10% of patients.

Côte d'Ivoirecerebral toxoplasmosis · VIH/sidaobserved 2010published 2014Journal of the International AIDS Societyeurope_pmcdocument of 22 observationsDOI 10.7448/ias.17.1.18797

4.9 per_100_person-yearsHIV incidence among regular blood donors in Abidjan decreased from 4.9 per 100 person-years in 1992–1994 to 0.07 per 100 person-years in 2010–2012.

Côte d'IvoireVIH/sidaobserved 1992–1994published 2018Open forum infectious diseaseseurope_pmcdocument of 12 observations

62.2 odds_ratioKaposi sarcoma was associated with HIV infection with an odds ratio of 62.2.

Côte d'Ivoiresarcome de Kaposi · VIH/sidapublished 2012PloS oneeurope_pmcdocument of 7 observationsDOI 10.1371/journal.pone.0048108

4,400 DALYs_per_yearThe no switch policy was predicted to lead to an overall increased number of DALYs incurred of mean 4400 per year compared with the switch policy.

Côte d'IvoireVIH/sidapublished 2025The lancet. HIVeurope_pmcdocument of 6 observations

15.9 per_100_person-yearsThe incidence of first serious event among HIV-infected adults receiving antiretroviral treatment was 15.9 per 100 person-years within the first year.

Côte d'IvoireVIH/sidapublished 2013BMC infectious diseaseseurope_pmcdocument of 10 observationsDOI 10.1186/1471-2334-13-607

1.9 per_100_person-yearsParticipants with HBsAg and high HBV DNA had an all-cause mortality incidence of 1.9 per 100 person-years.

Côte d'Ivoirehépatite B · VIH/sidaobserved 2008 and 2015published 2021Journal of viral hepatitiseurope_pmcdocument of 5 observations

4.7 log10 copies/mLPatients in the immediate group had a median plasma HIV-1 RNA of 4.7 log10 copies/mL at baseline.

Côte d'IvoireVIH/sidapublished 2021The Journal of antimicrobial chemotherapyeurope_pmcdocument of 8 observations

7 %Among hospitalized HIV-positive adults in West Africa who died, sepsis was a fatal disease in 7% of deaths.

Côte d'Ivoiresepsis · VIH/sidaobserved 2010published 2014Journal of the International AIDS Societyeurope_pmcdocument of 22 observationsDOI 10.7448/ias.17.1.18797

14.4 %In a cohort of HIV-infected patients of sub-Saharan African origin, the cumulative incidence of metabolic syndrome was 14.4% after 3 years of combined antiretroviral therapy.

Côte d'Ivoiresyndrome métabolique · VIH/sidapublished 2015AIDS research and human retroviruseseurope_pmcdocument of 7 observations

31 %Oral candidiasis was present in 31% of the HIV-infected patients.

Côte d'Ivoireoral candidiasis · VIH/sidaobserved January 2005-July 2015published 2018The Pan African medical journaleurope_pmcdocument of 9 observations

900 USDWhen the least harmful and most efficient alternatives for achieving budget cuts of 10% to 20% are applied, every year of life lost will save roughly $900 in HIV-related outlays in RSA.

Côte d'IvoireVIH/sidapublished 2017Annals of internal medicineeurope_pmcdocument of 6 observations

5.1 log10 copies/mLPatients in the deferred group who started ART had a higher median plasma HIV-1 RNA (5.1 log10 copies/mL) at baseline.

Côte d'IvoireVIH/sidapublished 2021The Journal of antimicrobial chemotherapyeurope_pmcdocument of 8 observations

4.4 %The HIV prevalence in the referent group (n=792) was 4.4% [CI 3.0-5.8].

Côte d'IvoireVIH/sidapublished 2015Cancer epidemiologyeurope_pmcdocument of 7 observations

2.67 hazard_ratioIn univariate analysis, the hazard ratio of death was 2.67 (95% CI, 1.68–4.22) for patients with HIV-1 DNA ≥3 log10 copies/million PBMC vs. others in the Temprano trial.

Côte d'IvoireVIH/sidapublished 2020EBioMedicineeurope_pmcdocument of 7 observations

8.5 %HIV incidence among female sex workers who reported not always using condoms with their clients in Côte d'Ivoire was 8.5%.

Côte d'IvoireVIH/sidaobserved 2016-2017published 2022PloS oneeurope_pmcdocument of 10 observationsDOI 10.1371/journal.pone.0271988

75 /mm³Among hospitalized HIV-positive adults in West Africa, the median CD4 count was 75/mm³.

Côte d'IvoireVIH/sidaobserved 2010published 2014Journal of the International AIDS Societyeurope_pmcdocument of 22 observationsDOI 10.7448/ias.17.1.18797

17.7 %The median rate of loss to follow-up was 17.7%.

Côte d'IvoireVIH/sidapublished 2010Le Mali medicaleurope_pmcdocument of 17 observations

20 %Mortality in adults admitted to hospital living with HIV was 20%.

Côte d'IvoireVIH/sidapublished 2015The lancet. HIVeurope_pmcdocument of 8 observations

1.2 %At month 6, 1.2% of HIV-1-infected adults on zidovudine + lamivudine + efavirenz were dead.

Côte d'IvoireVIH/sidaobserved month 6published 2006Journal of acquired immune deficiency syndromes (1999)europe_pmcdocument of 9 observationsDOI 10.1097/01.qai.0000219777.04927.50